Quick Answer
Traws Pharma, Inc. reported Diluted EPS of $35.21 per share (loss) for fiscal year 2024.
Traws Pharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$35.21 | -56.0% |
| 2023 | -$22.57 | -2380.2% |
| 2022 | -$0.91 | +5.2% |
| 2021 | -$0.96 | +55.8% |
| 2020 | -$2.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.34 | +77.2% | -209.1% |
| June 30, 2025 | -$0.11 | +99.5% | -105.3% |
| March 31, 2025 | $2.09 | +135.3% | +240.3% |
| September 30, 2024 | -$1.49 | +73.6% | +92.7% |
| June 30, 2024 | -$20.52 | -10160.0% | -246.6% |
| March 31, 2024 | -$5.92 | -2014.3% | -5.0% |
| September 30, 2023 | -$5.64 | -2069.2% | -2720.0% |
| June 30, 2023 | -$0.20 | -5.3% | +28.6% |
- Traws Pharma, Inc. showed a decrease of -56.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Traws Pharma, Inc.’s diluted eps has declined by 1522.6% (from $2.17 per share (loss) to $35.21 per share (loss)).
- The most recent figure is from Traws Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: